LAMTOR3

Ragulator complex protein LAMTOR3 · Q9UHA4 · LAMTOR3 on Sugi Atlas →

0 patent compounds predicted against LAMTOR3, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to LAMTOR3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Doxycycline In Lymphangioleiomyomatosis (LAM) PHASE4COMPLETED
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
Feasibility of [11C]Acetate-PET in LAM and TSC PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Effect of Loratadine in Lymphangioleiomyomatosis PHASE2UNKNOWN
Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM PHASE2UNKNOWN
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) PHASE1/PHASE2COMPLETED
COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC PHASE2COMPLETED
Letrozole for Lymphangioleiomyomatosis PHASE2COMPLETED
RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM PHASE1/PHASE2COMPLETED
Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) PHASE1/PHASE2COMPLETED
Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome PHASE2WITHDRAWN
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study PHASE2RECRUITING
Optimizing IV Gentamicin in JEB PHASE1/PHASE2UNKNOWN
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Glutamine Supplementation in People With Immune Dysregulation EARLY_PHASE1WITHDRAWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Characterization of the Natural History of LAMA2-RD and Identification of Novel Disease Biomarkers nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry) nanRECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
LAMA2 Genetic Correction nanCOMPLETED
LAMA2-related Muscular Dystrophy Brain Study nanWITHDRAWN
Retrospective Natural History Study of Infants and Toddlers With LAMA2-CMD nanCOMPLETED
Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma nanCOMPLETED
MEHMO Natural History and Biomarkers nanRECRUITING
Clinical and Genetic Examinations of Dilated Cardiomyopathy nanCOMPLETED
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a LAMTOR3 binder may also engage these)

ProteinNameSimilarity
Q5ZIP2 1.000 Q5ZIP2 →
Q5R3Z6 1.000 Q5R3Z6 →
B5G0G8 1.000 B5G0G8 →
Q17QQ1 1.000 Q17QQ1 →
O88653 0.995 O88653 →
Q5U204 0.994 Q5U204 →
B4F6Y3 0.981 B4F6Y3 →
Q6Y228 0.974 Q6Y228 →
Q503S6 0.966 Q503S6 →
Q7T0V2 0.964 Q7T0V2 →
Q4SSF5 0.957 Q4SSF5 →
Q9Y296 0.939 Q9Y296 →
Q63ZJ2 0.936 Q63ZJ2 →
Q7T0T2 0.936 Q7T0T2 →
Q6DF40 0.935 Q6DF40 →
Q9ES56 0.935 Q9ES56 →
Q6PC62 0.933 Q6PC62 →
Q69BT7 0.932 Q69BT7 →
Q5R9J9 0.932 Q5R9J9 →
Q2TBL9 0.931 Q2TBL9 →
Q9CQC8 0.931 Q9CQC8 →
A7YWS7 0.931 A7YWS7 →
Q4R5H6 0.929 Q4R5H6 →
Q8MJJ1 0.929 Q8MJJ1 →
Q5R8I6 0.928 Q5R8I6 →
Q9WVJ2 0.928 Q9WVJ2 →
B5XGE7 0.928 B5XGE7 →
Q68FS2 0.927 Q68FS2 →
Q6Z844 0.926 Q6Z844 →
O55029 0.926 O55029 →